Patient | Time-points (min) | Gender | Age | Location | Tumor type | differentiation | Tumor % Peptide array | Tumor % LC–MS–MS |
---|---|---|---|---|---|---|---|---|
1 | 0 | Male | 62 | Caecum | Adenocarcinoma | Good/intermediate | 50% | 50% |
30 | 80% | |||||||
60 | 95% | 70% | ||||||
90 | 95% | |||||||
120 | 60% | 70% | ||||||
150 | 80% | |||||||
180 | 70% | 70% | ||||||
2 | 0 | Male | 60 | Rectum | Mucinous | 20% | ||
30 | 7.5% | |||||||
60 | 5% | |||||||
90 | 10% | |||||||
120 | 10% | |||||||
150 | 20% | |||||||
180 | 20% | |||||||
3 | 0 | Male | 74 | Sigmoid | Adenocarcinoma | Good/intermediate | 50% | |
30 | 25% | |||||||
60 | 25% | |||||||
90 | 25% | |||||||
120 | 25% | |||||||
150 | 25% | |||||||
180 | 37.5% | |||||||
4 | 0 | Female | 49 | Caecum | Adenocarcinoma | Good/intermediate | 75% | 70% |
30 | 50% | |||||||
60 | 40% | 55% | ||||||
90 | 30% | |||||||
120 | 20% | 25% | ||||||
150 | 70% | |||||||
180 | 70% | 35% | ||||||
5 | 0 | Male | 64 | Ascending colon | Adenocarcinoma | Good/intermediate | 25% | 30% |
30 | 50% | |||||||
60 | 50% | 60% | ||||||
90 | 50% | |||||||
120 | 50% | 40% | ||||||
150 | 50% | |||||||
180 | 50% | 40% |